Bioseparations is the isolation or separation of target molecules from a biochemical reaction without damaging the organisms concerned, for example, extracting antibodies from a heterogeneous sample. Using exactly the same binding process for immunoassays, Mix&Go™ can be used to selectively bind target biomolecules and then extract them from samples.

We are currently working on a number of bioseparations projects, the most notable of which is for clinical sample pre-treatment.

Bioseparations: Clinical Sample Interference

Interference is a substance present in a patient specimen that can alter the correct value of the result by interfering with antibody binding, or that can increase or decrease assay signal by bridging, steric hindrance, or autoantibody mechanisms. Erroneous results can impact patient care, and can lead to unnecessary invasive, diagnostic or therapeutic procedures, or failure to treat a patient with a false negative test result.

The fact is all immunoassays are susceptible to sample specific interference and there is a clinical need for a simple, inexpensive, automatable and effective solution to mitigate sample specific interferences.

Mix&Go™ can be used to functionalise a plethora of different surfaces for subsequent binding and co-coating of highly functional proteins to pre-treat clinical samples and deplete interference.

In the video below, Joshua Soldo, VP of Scientific Affairs, Anteo Technologies (Anteo Diagnostics’ operating subsidiary), presents the possibilities of our bioseparations patent.

Topic: Mitigating Sample Specific Interferences in Clinical Samples
Venue: AACC OEM Lecture Series. Room: Exhibit Hall Theater 1
Recorded: July 2015, Atlanta GA